TY - JOUR
T1 - Anti-B cell therapy with rituximab as induction therapy in renal transplantation
AU - Joosten, I.
AU - Baas, M. C.
AU - Kamburova, E. G.
AU - van den Hoogen, M. W. F.
AU - Koenen, H. J. P. M.
AU - Hilbrands, L. B.
PY - 2014/10
Y1 - 2014/10
N2 - Traditionally, antirejection therapy in organ transplantation has mainly been directed at T cells. During recent years, the role of B cells in acute rejection has attracted more attention. In the Radboud University Medical Center (Nijmegen, The Netherlands) we performed a randomized, placebo controlled study to assess the efficacy and safety of rituximab as induction therapy after renal transplantation. In parallel we investigated the effects of rituximab on the numbers and function of B and T cells. An overview of the results, which have largely been published in peer reviewed papers, is presented below. (C) 2014 Elsevier B.V. All rights reserved.
AB - Traditionally, antirejection therapy in organ transplantation has mainly been directed at T cells. During recent years, the role of B cells in acute rejection has attracted more attention. In the Radboud University Medical Center (Nijmegen, The Netherlands) we performed a randomized, placebo controlled study to assess the efficacy and safety of rituximab as induction therapy after renal transplantation. In parallel we investigated the effects of rituximab on the numbers and function of B and T cells. An overview of the results, which have largely been published in peer reviewed papers, is presented below. (C) 2014 Elsevier B.V. All rights reserved.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000347586000006&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.trim.2014.09.011
DO - 10.1016/j.trim.2014.09.011
M3 - Article
C2 - 25270152
SN - 0966-3274
VL - 31
SP - 207
EP - 209
JO - Transplant Immunology
JF - Transplant Immunology
IS - 4
ER -